Access to Breast Cancer Diagnosis Act of 2025

1) HR 3037, the Access to Breast Cancer Diagnosis Act of 2025, was introduced in the House on April 28, 2025, by Rep. Dingell (D-MI) and referred to the Committees on Energy and Commerce and Ways and Means. The bill eliminates cost-sharing (deductibles, coinsurance, copayments) for diagnostic and supplemental breast examinations in group health plans and individual insurance. It is in early legislative stage with no committee action to date. 2) The bill does NOT authorize new government spending or appropriations. It imposes a coverage mandate on private insurers and group health plans. The mechanism is regulatory: insurers must cover diagnostic breast exams at zero patient cost-sharing. This increases the number of exams performed because the out-of-pocket cost barrier is removed. The economic impact transfers money from insurers' claims budgets to providers' revenue. No government funding is involved. 3) Structural winners are diagnostic imaging providers $DGX (Quest Diagnostics) and $LH (Labcorp). Both derive significant revenue from diagnostic breast imaging services (mammography, ultrasound, MRI). Removing cost-sharing is expected to increase utilization volumes by an estimated 10-20%, driving incremental revenue. Structural losers are insurers $CVS (Aetna), $UNH (UnitedHealthcare), and $HUM (Humana), who will pay for more exams without collecting patient cost-sharing, increasing their medical loss ratios on these services. Hospitals ($HCA) also benefit from increased imaging volumes. 4) Real market data shows $DGX at $195.15 (30-day change: -0.42%) and $LH at $261.94 (30-day change: -1.83%). Both diagnostic stocks have been flat to slightly down over the past month, suggesting the market has not priced in any legislative catalyst. Insurers $CVS ($83.62, +16.42% 30-day) and $HUM ($241.06, +39.03% 30-day) have rallied significantly, indicating sector momentum unrelated to this bill's prospects. The lack of price reaction in $DGX and $LH to this bill's introduction confirms its early-stage nature. 5) The legislative path is lengthy: the bill must pass both House committees, receive floor votes in both chambers, and be reconciled with its Senate companion S1500. With 37 cosponsors and a bipartisan sponsorship group (Dingell, Fitzpatrick, Wasserman Schultz), the bill has better support than average for an early-stage bill. However, committee referral with zero subsequent action indicates no near-term passage probability. If the bill gains momentum through committee markups in late 2025 or 2026, provider stocks would materially reprice upward.